Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03462212 |
| Title | Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination (MITO25) |
| Acronym | MITO25 |
| Recruitment | Recruiting |
| Gender | female |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | ITA |